Company Filing History:
Years Active: 1996-1998
Title: **So Bjoern: Innovator in Spasmolytic Polypeptides**
Introduction
So Bjoern, located in Lyngby, DK, is an accomplished inventor with a portfolio of seven patents. His innovative work primarily revolves around spasmolytic polypeptides, contributing to advancements in biochemical research and therapeutic applications.
Latest Patents
Bjoern's latest patents demonstrate his expertise in the field. They include:
1. **Human Spasmolytic Polypeptide in Glycosylated Form**
2. **Human Kunitz-type Protease Inhibitor Variants**
3. **A Variant of the C-terminal Kunitz-type Protease Inhibitor Domain of the α3 Chain of Human Type VI Collagen**: This variant comprises a specific amino acid sequence with substantial implications for medical and therapeutic applications.
Career Highlights
Bjoern is associated with Novo Nordisk A/S, a leading global healthcare company dedicated to innovation in diabetes care and other serious chronic conditions. His role involves research and development, pushing the boundaries of therapeutic possibilities through his unique inventions.
Collaborations
Throughout his career, Bjoern has collaborated with several notable individuals, including his coworkers, Fanny Norris and Kjeld Norris. These collaborations reflect a dynamic environment where innovation thrives through teamwork and shared expertise.
Conclusion
So Bjoern stands out as a significant figure in the field of biochemical innovation, with a strong patent portfolio that showcases his dedication to advancing medical science. His contributions continue to inspire and impact the industry, making his work influential in the realm of spasmolytic polypeptides.